| scholarly article | Q13442814 |
| P2093 | author name string | Jinhui Wang | |
| Joseph E. Rabinowitz | |||
| Susan M. Faust | |||
| P2860 | cites work | Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism | Q24515072 |
| Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression | Q24529167 | ||
| Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions | Q24531466 | ||
| Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps | Q24533013 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells | Q24538924 | ||
| Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA | Q24562760 | ||
| Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 | ||
| Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year | Q24634801 | ||
| Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector | Q27647639 | ||
| ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES | Q28202390 | ||
| Rapid evolution of a protein in vitro by DNA shuffling | Q28245873 | ||
| A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner | Q28256353 | ||
| Effect of gene therapy on visual function in Leber's congenital amaurosis | Q28277981 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery | Q30483589 | ||
| Steps toward mapping the human vasculature by phage display. | Q30804451 | ||
| Inverting enantioselectivity by directed evolution of hydantoinase for improved production of L-methionine | Q30843376 | ||
| Peptides targeting caspase inhibitors | Q30882598 | ||
| Molecular breeding of viruses | Q30898162 | ||
| Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors | Q30975099 | ||
| Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors | Q31036743 | ||
| In vivo phage display and vascular heterogeneity: implications for targeted medicine | Q31060394 | ||
| In vitro selection of viral vectors with modified tropism: the adeno-associated virus display | Q33187644 | ||
| Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses | Q33230629 | ||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors | Q33232270 | ||
| The epitope recognized by rituximab | Q33243656 | ||
| Structure determination of adeno-associated virus 2: three complete virus particles per asymmetric unit | Q45723313 | ||
| Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography | Q45731650 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q45745995 | ||
| A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome | Q45766163 | ||
| A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis | Q45867380 | ||
| Clinical gene transfer studies for hemophilia B. | Q45875059 | ||
| Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. | Q45880182 | ||
| Immune responses to AAV in a phase I study for Canavan disease | Q48620414 | ||
| Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
| Percutaneous Transendocardial Delivery of Self-complementary Adeno-associated Virus 6 Achieves Global Cardiac Gene Transfer in Canines | Q64375839 | ||
| Characterization of a nuclear localization signal of canine parvovirus capsid proteins | Q74038314 | ||
| Modulation of the immune response by systemic targeting of antigens to lymph nodes | Q77220667 | ||
| Gene therapy for haemophilia | Q80702723 | ||
| Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations | Q84583870 | ||
| Isolation of targeted AAV2 vectors from novel virus display libraries | Q33256517 | ||
| Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy | Q33301839 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
| Chapter 4. Screening phage-display Peptide libraries for vascular targeted peptides | Q33385870 | ||
| Chimeric AAV Cap sequences alter gene transduction | Q33411107 | ||
| A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection | Q33411254 | ||
| Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries | Q33428576 | ||
| Directed evolution of adeno-associated virus for glioma cell transduction | Q33484220 | ||
| Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity | Q33490137 | ||
| Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). | Q33521174 | ||
| Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy | Q33691883 | ||
| Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression | Q33786039 | ||
| Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction | Q33802664 | ||
| Dynamin is required for recombinant adeno-associated virus type 2 infection | Q33825510 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| Insertional mutagenesis of AAV2 capsid and the production of recombinant virus | Q33883772 | ||
| AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells | Q33931609 | ||
| DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids | Q33951407 | ||
| Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo | Q34070164 | ||
| Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells | Q34090326 | ||
| A viral phospholipase A2 is required for parvovirus infectivity | Q34101246 | ||
| The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity | Q34124491 | ||
| Ligand-directed targeting of genes to the site of disease | Q34168868 | ||
| RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism | Q34194223 | ||
| Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties | Q34228552 | ||
| Identification of PDGFR as a receptor for AAV-5 transduction | Q34264144 | ||
| The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection | Q34331386 | ||
| Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. | Q34433170 | ||
| Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo | Q34472029 | ||
| AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection | Q34486863 | ||
| Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat | Q34556048 | ||
| Self-complementary AAV vectors; advances and applications | Q34804660 | ||
| Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. | Q35025591 | ||
| Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment | Q39748126 | ||
| Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo | Q39979752 | ||
| Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction | Q40034184 | ||
| Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction | Q40111373 | ||
| Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab | Q40144650 | ||
| Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging | Q40335965 | ||
| Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo | Q40499221 | ||
| AAV serotype 2 vectors preferentially integrate into active genes in mice | Q40643545 | ||
| Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. | Q40726384 | ||
| Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes | Q40726705 | ||
| Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy | Q41008247 | ||
| Hepatic AAV gene transfer and the immune system: friends or foes? | Q41277780 | ||
| Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter | Q41678112 | ||
| Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 | ||
| Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. | Q41972673 | ||
| Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. | Q42024301 | ||
| Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry | Q42051675 | ||
| Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization | Q42203239 | ||
| Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus | Q43173416 | ||
| Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors | Q43740107 | ||
| Real-time single-molecule imaging of the infection pathway of an adeno-associated virus | Q43812869 | ||
| Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice | Q43847196 | ||
| Epidemiology of adenovirus-associated virus infection in a nursery population | Q44631695 | ||
| Release of canine parvovirus from endocytic vesicles | Q44673556 | ||
| Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. | Q45259698 | ||
| Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts | Q45387382 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo | Q45413958 | ||
| Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus | Q45422552 | ||
| One year transgene expression with adeno-associated virus cardiac gene transfer | Q45479985 | ||
| Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 | ||
| Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies | Q45709087 | ||
| Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors | Q45721911 | ||
| Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors | Q45721934 | ||
| Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver | Q45722297 | ||
| Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus | Q39306165 | ||
| Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates | Q39504342 | ||
| Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors | Q39589898 | ||
| Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation | Q39602167 | ||
| Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection | Q35083665 | ||
| The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9 | Q35101411 | ||
| Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. | Q35140088 | ||
| Receptor targeting of adeno-associated virus vectors | Q35165723 | ||
| Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells | Q35228018 | ||
| Can genes transduced by adeno-associated virus vectors elicit or evade an immune response? | Q35613147 | ||
| Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. | Q35621815 | ||
| Notch1 augments intracellular trafficking of adeno-associated virus type 2. | Q35635454 | ||
| Immune implications of gene therapy for hemophilia | Q35760790 | ||
| Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy | Q35799349 | ||
| Immune responses to gene therapy vectors: influence on vector function and effector mechanisms | Q35904408 | ||
| Preclinical and clinical gene therapy for haemophilia | Q35915704 | ||
| Targeted integration of adeno-associated virus (AAV) into human chromosome 19 | Q35936149 | ||
| Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice | Q36144935 | ||
| New recombinant serotypes of AAV vectors. | Q36172991 | ||
| Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. | Q36238762 | ||
| Tolerance induction by viral in vivo gene transfer | Q36320026 | ||
| Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics | Q36460379 | ||
| Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors | Q36509889 | ||
| New approaches in the therapy of cardiomyopathy in muscular dystrophy | Q36705183 | ||
| Organ targeting in vivo using phage display peptide libraries | Q36795550 | ||
| Yeast surface display for screening combinatorial polypeptide libraries | Q36865126 | ||
| Adeno-associated virus general transduction vectors: analysis of proviral structures | Q36868692 | ||
| Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants | Q36893013 | ||
| Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function | Q36918727 | ||
| Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics | Q36937189 | ||
| Immunity to adeno-associated virus vectors in animals and humans: a continued challenge | Q37127246 | ||
| Clinical gene therapy using recombinant adeno-associated virus vectors | Q37140649 | ||
| Tailoring the AAV vector capsid for gene therapy. | Q37340302 | ||
| Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. | Q37364786 | ||
| Gene therapy for hemophilia: clinical trials and technical tribulations | Q37421639 | ||
| Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids | Q38299901 | ||
| Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma | Q38436809 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 793-802 | |
| P577 | publication date | 2010-10-26 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | The next step in gene delivery: molecular engineering of adeno-associated virus serotypes | |
| The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes | |||
| P478 | volume | 50 |
| Q26849375 | A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme |
| Q37272261 | Adeno-associated virus-mediated gene therapy for metabolic myopathy |
| Q40525635 | Assembly, Engineering and Applications of Virus-Based Protein Nanoparticles |
| Q36321364 | Assessment of hazard risk associated with the intravenous use of viral vectors in rodents. |
| Q34464281 | Beyond the hammer and the scalpel: selective circuit control for the epilepsies |
| Q37965045 | Cardiac gene therapy: from concept to reality |
| Q42438941 | Cardiovascular science: opportunities for translating research into improved care |
| Q35005408 | Characterization of naturally-occurring humoral immunity to AAV in sheep |
| Q30525258 | Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network |
| Q36825693 | Disruption of Microtubules Post-Virus Entry Enhances Adeno-Associated Virus Vector Transduction. |
| Q39031877 | Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma |
| Q30420426 | Efficient single-cell poration by microsecond laser pulses |
| Q53104041 | Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease. |
| Q40559074 | Expression mediated by three partial sequences of the human tyrosine hydroxylase promoter in vivo |
| Q40804917 | Flexible, AAV-equipped Genetic Modules for Inducible Control of Gene Expression in Mammalian Brain |
| Q51846343 | Gene Therapy Used in Cancer Treatment. |
| Q37994717 | Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases |
| Q26799437 | Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation |
| Q83556143 | Gene therapy for heart failure |
| Q38073152 | Gene therapy for heart failure: where do we stand? |
| Q35340196 | Gene therapy for the nervous system: challenges and new strategies |
| Q39348354 | Guiding plant virus particles to integrin-displaying cells |
| Q39834994 | Inducible and combinatorial gene manipulation in mouse brain |
| Q40705086 | Inexpensive, serotype-independent protocol for native and bioengineered recombinant adeno-associated virus purification |
| Q30412532 | Laser-induced microbubble poration of localized single cells |
| Q36037919 | MicroRNA therapeutics in cardiovascular medicine |
| Q43139168 | Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity |
| Q35078590 | Recombinant AAV-directed gene therapy for type I glycogen storage diseases |
| Q34297263 | Significance and applications of nanoparticles in siRNA delivery for cancer therapy |
| Q92489485 | Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges |
| Q37393827 | The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer |
| Q37019105 | Tools, methods, and applications for optophysiology in neuroscience |
| Q30538923 | Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo |
| Q38655270 | Virus-Derived Peptides for Clinical Applications |
Search more.